PUBLISHER: DelveInsight | PRODUCT CODE: 2167082
PUBLISHER: DelveInsight | PRODUCT CODE: 2167082
DelveInsight's, "Huntington's Disease - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Huntington's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Huntington's disease: Understanding
Huntington's disease: Overview
Huntington's disease (HD) is a rare, progressive, inherited neurodegenerative disorder that affects movement, cognition, and behavior. The disease is characterized by uncontrolled movements known as chorea, psychiatric disturbances, emotional changes, and gradual cognitive decline leading to dementia. Symptoms usually begin between 30 and 50 years of age, although juvenile forms can occur earlier. Huntington's disease progressively worsens over time and significantly affects daily functioning, independence, and quality of life. It is inherited in an autosomal dominant manner, meaning that a child of an affected parent has a 50% chance of inheriting the disorder.
Huntington's disease is caused by a mutation in the huntingtin (HTT) gene located on chromosome 4. The mutation involves an abnormal expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats within the gene. Normal individuals typically have fewer than 35 CAG repeats, whereas people with Huntington's disease usually have 36 or more repeats. The expanded repeats result in the production of an abnormal huntingtin protein that becomes toxic to neurons. The disease follows an autosomal dominant inheritance pattern, and larger repeat expansions are often associated with earlier disease onset and more severe progression, a phenomenon known as anticipation.
The pathophysiology of Huntington's disease involves progressive neuronal degeneration, particularly in the striatum and cerebral cortex. The mutant huntingtin protein undergoes abnormal folding and aggregation, disrupting multiple cellular processes including transcription, mitochondrial function, axonal transport, synaptic signaling, and protein degradation pathways. Neuronal loss primarily affects gamma-aminobutyric acid (GABA)-producing medium spiny neurons in the caudate nucleus and putamen, leading to imbalance in motor control pathways and resulting in choreiform movements. As the disease progresses, widespread cortical degeneration contributes to cognitive impairment, psychiatric symptoms, and behavioral disturbances. Neuroinflammation, oxidative stress, and excitotoxicity are also believed to contribute to neuronal injury and disease progression.
Diagnosis of Huntington's disease is based on clinical evaluation, family history, neurological examination, and genetic testing. Physicians assess characteristic motor symptoms such as chorea, impaired coordination, abnormal eye movements, and gait disturbances, along with psychiatric and cognitive changes. Confirmation is obtained through genetic testing demonstrating expanded CAG repeats in the HTT gene. Brain imaging studies such as magnetic resonance imaging (MRI) or computed tomography (CT) may show atrophy of the caudate nucleus and cerebral cortex. Predictive genetic testing is available for asymptomatic individuals with a family history of the disease, although genetic counseling is strongly recommended before testing because of the psychological and ethical implications.
There is currently no cure for Huntington's disease, and treatment focuses on symptom management and supportive care. Medications such as tetrabenazine and deutetrabenazine are approved to reduce chorea by depleting dopamine. Antipsychotic drugs, antidepressants, and mood stabilizers may be used to manage psychiatric symptoms including depression, anxiety, irritability, and psychosis. Physical therapy, occupational therapy, speech therapy, and nutritional support are important components of multidisciplinary care to maintain mobility, communication, and quality of life. Research is ongoing into disease-modifying therapies including gene silencing approaches, antisense oligonucleotides, RNA-targeted therapies, and neuroprotective treatments aimed at reducing mutant huntingtin protein production and slowing disease progression.
"Huntington's Disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Huntington's disease pipeline landscape is provided which includes the disease overview and Huntington's disease treatment guidelines. The assessment part of the report embraces, in depth Huntington's disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Huntington's disease Emerging Drugs Chapters
This segment of the Huntington's disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Huntington's disease Emerging Drugs
HTT227 (formerly referred as PCT318, also known as votoplam) is an orally bioavailable small molecule designed to reduce the production of the mutant huntingtin protein responsible for neuronal injury and degeneration in Huntington's disease. The compound effectively penetrates the blood-brain barrier and is characterized by its selectivity, titratability, and lack of efflux. Currently, HTT227 is in Phase III clinical development for the treatment of Huntington's disease, reflecting its potential as a disease-modifying therapeutic.
VO659 is an investigational antisense oligonucleotide (ASO) therapy developed by Vico Therapeutics for the treatment of Huntington's disease (HD). It is designed to directly target the expanded CAG repeat mutation underlying HD and other polyglutamine diseases. VO659 employs an allele-preferential mechanism, preferentially binding to expanded CAG repeats in the mutant huntingtin (HTT) mRNA and sterically blocking its translation, thereby reducing production of toxic mutant huntingtin (mHTT) protein while aiming to preserve expression of wild-type HTT. The therapy is administered by intrathecal injection and is being evaluated in a Phase I/IIa clinical trial for Huntington's disease.
SRP-1005 is an investigational small interfering RNA (siRNA) therapy being developed by Sarepta Therapeutics, Inc. for the treatment of Huntington's disease. SRP-1005 is designed to reduce the production of mutant huntingtin (HTT) protein, the toxic protein responsible for neurodegeneration in Huntington's disease. The mechanism of action involves RNA interference technology that targets HTT messenger RNA (mRNA) for degradation, thereby lowering huntingtin protein expression in the brain. SRP-1005 utilizes an advanced transferrin receptor protein 1 (TfR1)-based delivery platform with monovalent fragment antigen binding (fAb) technology to enable efficient penetration across the blood-brain barrier and delivery into the central nervous system. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Huntington's disease.
RGT-0474060 is an oral bioavailable small molecule designed to inhibit PMS1 RNA and protein expression, effectively to modulate splicing of CAG (cytosine-adenine-guanine) repeat expansion known to cause Huntington's disease. In February 2026, Rgenta Therapeutics, announced that preclinical data from its new Huntington's disease (HD) drug candidate targeting PMS1, RGT-0474060, were presented at the 21st Annual HD Therapeutics Conference and the preclinical data have demonstrated robust mechanism-linked functional activity for PMS1 reduction, dose-dependent pharmacokinetics, oral, brain-penetration, and clinically relevant RNA reduction in brain tissues with a well-tolerated safety profile. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Huntington's disease.
Huntington's disease: Therapeutic Assessment
This segment of the report provides insights about the different Huntington's disease drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 50+ key companies which are developing the therapies Huntington's disease. The companies which have their Huntington's disease drug candidates in the most advanced stage, i.e. Phase III include, Novartis AG, and others.
DelveInsight's report covers around 55+ products under different phases of clinical development like
Huntington's disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Huntington's disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Huntington's disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Huntington's disease drugs.
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Huntington's Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Huntington's Disease- DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
HTT227: Novartis AG /PTC Therapeutics
Mid Stage Products (Phase II)
Drug name: Company Name
Early Stage Products (Phase I/II)
VO659: Vico Therapeutics
Early Stage Products (Phase I)
SRP-1005: Sarepta Therapeutics, Inc./Arrowhead Pharmaceuticals
Preclinical and Discovery Stage Products
RGT-0474060: Rgenta Therapeutics
Inactive Products
Huntington's Disease Key Companies
Huntington's Disease Key Products
Huntington's Disease - Unmet Needs
Huntington's Disease - Market Drivers and Barriers
Huntington's Disease - Future Perspectives and Conclusion
Huntington's Disease Analyst Views
Huntington's Disease Key Companies